These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2947371)

  • 21. The sustained release of LH X RH agonist from LH X RH agonist-polymer composite in patients with prostatic cancer.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetu I; Yamazaki I; Suzuki K
    Prostate; 1986; 8(4):325-32. PubMed ID: 3086853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.
    Mason-Garcia M; Vigh S; Comaru-Schally AM; Redding TW; Somogyvari-Vigh A; Horvath J; Schally AV
    Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1547-51. PubMed ID: 3156381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men.
    Evans RM; Doelle GC; Alexander AN; Uderman HD; Rabin D
    J Clin Endocrinol Metab; 1984 May; 58(5):862-7. PubMed ID: 6423661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of prostatic cancer with an LH-RH agonist: the D Trp6 LH-RH. Preliminary results in 30 cases].
    Steg A; Chiche R; Boccon-Gibod L; Debré B; Duchier J; Schally AV
    Ann Urol (Paris); 1984 Dec; 18(6):388-92. PubMed ID: 6241820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group.
    Bischoff W
    J Int Med Res; 1990; 18 Suppl 1():103-13. PubMed ID: 2108882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monthly administration of the LH-RH analogue decapeptyl for long-term treatment of ovarian dysfunctions and estrogen-dependent disorders.
    Geisthoevel F; Hils K; Wieacker P; Breckwoldt M; Schultheiss H
    Int J Fertil; 1989; 34(4):262-70. PubMed ID: 2570764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of precocious puberty with LH-RH agonists. Multicenter study using D-Trp-6-LH-RH in a programmed-release form].
    Roger M; Chaussain JL; Bost M; Bozzola M; Colle M; Despert F; François R; Freycon F; Garandeau P; Malpuech G
    Rev Fr Gynecol Obstet; 1986 May; 81(5):297-305. PubMed ID: 2943013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH; Goldstein M; Kourides IA; Comite F; Bardin CW; Krieger DT
    J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D
    J Urol; 2003 May; 169(5):1738-41. PubMed ID: 12686821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma].
    Klippel KF; Winkler CJ; Jocham D; Rübben H; Möser B; Gulati A
    Urologe A; 1999 May; 38(3):270-5. PubMed ID: 10407987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group.
    Sharifi R; Soloway M
    J Urol; 1990 Jan; 143(1):68-71. PubMed ID: 2104638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer.
    Parmar H; Rustin G; Lightman SL; Phillips RH; Hanham IW; Schally AV
    Br Med J (Clin Res Ed); 1988 Apr; 296(6631):1229. PubMed ID: 2968130
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of prostatic cancers by periodic administration of a delayed-release preparation of D-Trp(6)-LHRH].
    Roger M; Duchier J; Lahlou N; Schally AV
    Ann Urol (Paris); 1986; 20(2):109-12. PubMed ID: 2424359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
    Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
    Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
    Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.